We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. By pressing "Accept All" or closing out of this banner, you accept our Privacy Policy and Terms of Service, revised from time to time, and you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties. You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
WBA Q1 Earnings and Revenues Beat Estimates, Stock Up in Pre-Market
Read MoreHide Full Article
Walgreens Boots Alliance, Inc. (WBA - Free Report) delivered adjusted earnings per share (EPS) of 51 cents in the first quarter of fiscal 2025, down 22.7% from the year-ago quarter’s figure (down 23.4% at constant exchange rate or CER). However, the figure topped the Zacks Consensus Estimate by 37.8%.
GAAP loss per share for the first quarter was 31 cents, wider than the year-ago quarter’s 8 cents loss.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Following the earnings announcement, WBA stock was up more than 10% in pre-market trading today.
WBA’s Revenues in Q1 and Fiscal 2025
Walgreens Boots recorded total sales of $39.46 billion in the fiscal first quarter, up 7.5% year over year and 6.1% at CER. The top line also surpassed the Zacks Consensus Estimate by 6.4%.
Segmental Insights of WBA’s Q1 Revenues
The company currently operates its business through three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare.
U.S. Retail Pharmacy
The segment’s sales increased 6.6% year over year to $30.9 billion in the fiscal first quarter. Comparable sales jumped 8.5% from the year-ago quarter’s levels.
Pharmacy sales were up 10.4% from the year-ago quarter’s figures, and comparable pharmacy sales increased 12.7%, each benefiting from higher brand inflation and prescription volume.
Retail sales fell 6.2%, and comparable retail sales were down 4.6% year over year, reflecting a weaker cough, cold and flu season, and lower sales in discretionary categories.
International
Revenues in the International division rose 10.2% on a year-over-year basis and increased 6.5% at CER to $6.4 billion in the fiscal first quarter.
In Germany, wholesale business sales increased 11.3% in the fiscal first quarter.
Boots UK sales rose 4.5% year over year. Boots UK’s comparable retail sales advanced 8.1%. Further, Boots UK’s comparable pharmacy sales rose 10.9% year over year.
U.S. Healthcare
U.S. Healthcare reported fiscal first-quarter revenues of $2.2 billion. Within the segment, VillageMD sales increased 9%, CareCentrix increased 16% and Shields increased 30%.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
The gross profit in the reported quarter edged up 0.1% year over year to $6.78 billion despite a 9.2% rise in the cost of sales. However, the gross margin contracted 126 basis points to 17.2%.
Selling, general and administrative expenses increased 2.4% year over year to $7.02 billion.
The company reported an adjusted operating loss of $236 million for the quarter compared with the year-ago period’s loss of $81 million.
WBA’s Liquidity & Cash Flow Position
Walgreens Boots exited the first quarter of fiscal 2025 with cash and cash equivalents of $859 million compared with $1.32 billion recorded in the fiscal 2024 end.
The total debt was $8.06 billion compared with $9.55 billion at the end of fiscal 2024.
The cumulative cash used by operating activities at the end of the first quarter of fiscal 2025 was $140 million compared with the year-ago period’s outflow of $281 million.
WBA’s Fiscal 2025 Outlook
Walgreens Boots reiterated its adjusted EPS guidance for fiscal 2025, expected in the range of $1.40-$1.80. The company expects growth in the U.S. Healthcare and International segments to be more than offset by a decline in U.S. Retail Pharmacy, a higher adjusted effective tax rate and reduced contributions from sale-leaseback and Cencora earnings.
The Zacks Consensus Estimate for the company’s fiscal 2025 earnings currently stands at $1.52 per share.
Our Take on WBA Stock
Walgreens Boots exited the first quarter of fiscal 2025 with revenues and earnings beating estimates. Each of the business segments demonstrated sales growth, which bodes well. The results reflected disciplined execution of 2025 priorities, including stabilizing the retail pharmacy by optimizing the footprint, controlling operating costs, improving cash flow and continuing to address reimbursement models. Although the full turnaround will take time, Walgreens Boots is encouraged by the early progress toward a sustainable, retail pharmacy-led operating model.
However, the bottom line decreased on a year-over-year basis. The contraction of gross margin and a wider adjusted operating loss in the quarter raise concerns.
Meanwhile, over the past few weeks, rumors have been circulating that Walgreens Boots may be considering a potential sale to Sycamore Partners, a private equity firm based in New York. Per a Wall Street Journal report, a deal could be finalized early this year, with the firm possibly selling portions of Walgreens’ business or teaming up with partners.
WBA’s Zacks Rank & Key Picks
Walgreens Boots currently carries a Zacks Rank #4 (Sell).
Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2024 adjusted EPS of $1.21, which topped the Zacks Consensus Estimate by 0.8%. Revenues of $10.64 billion beat the Zacks Consensus Estimate by 0.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ABT has an earnings yield of 4.5% compared to the industry’s 0.5%. The company’s earnings surpassed estimates in three of the trailing four quarters and broke even in one, the average surprise being 1.64%.
Cardinal Health, carrying a Zacks Rank #2, posted first-quarter fiscal 2025 adjusted EPS of $1.88, exceeding the Zacks Consensus Estimate by 9.8%. Revenues of $52.28 billion surpassed the Zacks Consensus Estimate by 2%.
CAH has an estimated long-term earnings growth rate of 10.5% compared to the industry’s 9.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 11.24%.
Haemonetics, carrying a Zacks Rank #2, reported a second-quarter fiscal 2025 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 2.8%. Revenues of $345.5 million topped the Zacks Consensus Estimate by 0.7%.
HAE has an estimated earnings growth rate of 15.9% for fiscal 2025 compared with the industry’s 12.2% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
WBA Q1 Earnings and Revenues Beat Estimates, Stock Up in Pre-Market
Walgreens Boots Alliance, Inc. (WBA - Free Report) delivered adjusted earnings per share (EPS) of 51 cents in the first quarter of fiscal 2025, down 22.7% from the year-ago quarter’s figure (down 23.4% at constant exchange rate or CER). However, the figure topped the Zacks Consensus Estimate by 37.8%.
GAAP loss per share for the first quarter was 31 cents, wider than the year-ago quarter’s 8 cents loss.
Find the latest EPS estimates and surprises on Zacks Earnings Calendar.
Following the earnings announcement, WBA stock was up more than 10% in pre-market trading today.
WBA’s Revenues in Q1 and Fiscal 2025
Walgreens Boots recorded total sales of $39.46 billion in the fiscal first quarter, up 7.5% year over year and 6.1% at CER. The top line also surpassed the Zacks Consensus Estimate by 6.4%.
Segmental Insights of WBA’s Q1 Revenues
The company currently operates its business through three reportable segments: U.S. Retail Pharmacy, International and U.S. Healthcare.
U.S. Retail Pharmacy
The segment’s sales increased 6.6% year over year to $30.9 billion in the fiscal first quarter. Comparable sales jumped 8.5% from the year-ago quarter’s levels.
Pharmacy sales were up 10.4% from the year-ago quarter’s figures, and comparable pharmacy sales increased 12.7%, each benefiting from higher brand inflation and prescription volume.
Retail sales fell 6.2%, and comparable retail sales were down 4.6% year over year, reflecting a weaker cough, cold and flu season, and lower sales in discretionary categories.
International
Revenues in the International division rose 10.2% on a year-over-year basis and increased 6.5% at CER to $6.4 billion in the fiscal first quarter.
In Germany, wholesale business sales increased 11.3% in the fiscal first quarter.
Boots UK sales rose 4.5% year over year. Boots UK’s comparable retail sales advanced 8.1%. Further, Boots UK’s comparable pharmacy sales rose 10.9% year over year.
U.S. Healthcare
U.S. Healthcare reported fiscal first-quarter revenues of $2.2 billion. Within the segment, VillageMD sales increased 9%, CareCentrix increased 16% and Shields increased 30%.
Walgreens Boots Alliance, Inc. Price, Consensus and EPS Surprise
Walgreens Boots Alliance, Inc. price-consensus-eps-surprise-chart | Walgreens Boots Alliance, Inc. Quote
WBA’s Q1 Margin Performance
The gross profit in the reported quarter edged up 0.1% year over year to $6.78 billion despite a 9.2% rise in the cost of sales. However, the gross margin contracted 126 basis points to 17.2%.
Selling, general and administrative expenses increased 2.4% year over year to $7.02 billion.
The company reported an adjusted operating loss of $236 million for the quarter compared with the year-ago period’s loss of $81 million.
WBA’s Liquidity & Cash Flow Position
Walgreens Boots exited the first quarter of fiscal 2025 with cash and cash equivalents of $859 million compared with $1.32 billion recorded in the fiscal 2024 end.
The total debt was $8.06 billion compared with $9.55 billion at the end of fiscal 2024.
The cumulative cash used by operating activities at the end of the first quarter of fiscal 2025 was $140 million compared with the year-ago period’s outflow of $281 million.
WBA’s Fiscal 2025 Outlook
Walgreens Boots reiterated its adjusted EPS guidance for fiscal 2025, expected in the range of $1.40-$1.80. The company expects growth in the U.S. Healthcare and International segments to be more than offset by a decline in U.S. Retail Pharmacy, a higher adjusted effective tax rate and reduced contributions from sale-leaseback and Cencora earnings.
The Zacks Consensus Estimate for the company’s fiscal 2025 earnings currently stands at $1.52 per share.
Our Take on WBA Stock
Walgreens Boots exited the first quarter of fiscal 2025 with revenues and earnings beating estimates. Each of the business segments demonstrated sales growth, which bodes well. The results reflected disciplined execution of 2025 priorities, including stabilizing the retail pharmacy by optimizing the footprint, controlling operating costs, improving cash flow and continuing to address reimbursement models. Although the full turnaround will take time, Walgreens Boots is encouraged by the early progress toward a sustainable, retail pharmacy-led operating model.
However, the bottom line decreased on a year-over-year basis. The contraction of gross margin and a wider adjusted operating loss in the quarter raise concerns.
Meanwhile, over the past few weeks, rumors have been circulating that Walgreens Boots may be considering a potential sale to Sycamore Partners, a private equity firm based in New York. Per a Wall Street Journal report, a deal could be finalized early this year, with the firm possibly selling portions of Walgreens’ business or teaming up with partners.
WBA’s Zacks Rank & Key Picks
Walgreens Boots currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks from the broader medical space are Abbott (ABT - Free Report) , Cardinal Health (CAH - Free Report) and Haemonetics (HAE - Free Report) .
Abbott, carrying a Zacks Rank #2 (Buy) at present, reported third-quarter 2024 adjusted EPS of $1.21, which topped the Zacks Consensus Estimate by 0.8%. Revenues of $10.64 billion beat the Zacks Consensus Estimate by 0.7%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
ABT has an earnings yield of 4.5% compared to the industry’s 0.5%. The company’s earnings surpassed estimates in three of the trailing four quarters and broke even in one, the average surprise being 1.64%.
Cardinal Health, carrying a Zacks Rank #2, posted first-quarter fiscal 2025 adjusted EPS of $1.88, exceeding the Zacks Consensus Estimate by 9.8%. Revenues of $52.28 billion surpassed the Zacks Consensus Estimate by 2%.
CAH has an estimated long-term earnings growth rate of 10.5% compared to the industry’s 9.6%. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 11.24%.
Haemonetics, carrying a Zacks Rank #2, reported a second-quarter fiscal 2025 adjusted EPS of $1.12, which surpassed the Zacks Consensus Estimate by 2.8%. Revenues of $345.5 million topped the Zacks Consensus Estimate by 0.7%.
HAE has an estimated earnings growth rate of 15.9% for fiscal 2025 compared with the industry’s 12.2% growth. The company’s earnings surpassed estimates in three of the trailing four quarters and missed in one, the average surprise being 2.82%.